Get the Stockscreener App
7.258
1.07%
-0.072
Cvrx Inc stock is traded at $7.258, with a volume of 186.80K.
It is down -1.07% in the last 24 hours and down -2.27% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$7.33
Open:
$7.33
24h Volume:
186.80K
Relative Volume:
0.72
Market Cap:
$190.29M
Revenue:
$47.26M
Net Income/Loss:
$-58.48M
P/E Ratio:
-2.6833
EPS:
-2.7049
Net Cash Flow:
$-40.45M
1W Performance:
+29.72%
1M Performance:
-2.27%
6M Performance:
-13.05%
1Y Performance:
-56.24%
1-Day Range:
$6.96
$7.34
1-Week Range:
$5.575
$7.84
52-Week Range:
$4.2993
$17.78
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
7.26 | 192.12M | 47.26M | -58.48M | -40.45M | -2.7049 |
|
ABT
Abbott Laboratories
|
107.16 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.24 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.75 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.30 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.72 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CVRx supports MU Health with first Barostim implant - Traders Union
The Truth About CVRx Inc: Wall Street’s Sleeping Giant You’re Not Watching (Yet) - AD HOC NEWS
CVRx Kicks Off One Of The Largest Heart Device Trials In History - Sahm
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI) and CVRx (CVRX) - The Globe and Mail
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating - 富途资讯
CVRx’s stock up as heart failure device to be trialled in expanded patient group - Yahoo Finance
CVRx launches major heart failure trial to expand Barostim therapy reach - Investing.com Australia
CVRx Initiates BENEFIT-HF Trial; Q4 Financial Report Coming Soon - RTTNews
Cvrx Announces Initiation Of Benefit-Hf, A Landmark Heart Failure Trial - TradingView
CVRx stock rises after announcing major heart failure clinical trial By Investing.com - Investing.com South Africa
CVRx stock rises after announcing major heart failure clinical trial - Investing.com
New heart implant trial could triple patients eligible for Barostim - Stock Titan
Activity Recap: Does Amarin Corporation plc Depositary Receipt have declining or rising EPSWall Street Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
The Technical Signals Behind (CVRX) That Institutions Follow - Stock Traders Daily
Movement Recap: Whats the beta of CVRx Inc stock2025 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
Fundamentals Check: Whats the beta of CVRx Inc stockBuy Signal & Smart Money Movement Tracker - baoquankhu1.vn
AI Stocks: What is the earnings history of CVRx IncQuarterly Market Review & AI Forecasted Stock Moves - baoquankhu1.vn
CVRx, Inc. (NASDAQ:CVRX) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
CVRx, Inc. (NASDAQ:CVRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Aug PostEarnings: Does Tootsie Roll Industries Inc have consistent dividend growthStock Surge & Detailed Earnings Play Alerts - baoquankhu1.vn
Aug Setups: Why is CVRx Inc stock going downQuarterly Portfolio Summary & Verified Technical Trade Signals - baoquankhu1.vn
Bull Bear: Should value investors consider CVRXJuly 2025 Recap & AI Driven Price Predictions - baoquankhu1.vn
Sentiment Review: Is LKQ Corporation stock a good pick for beginners2025 Market Overview & High Accuracy Swing Trade Signals - baoquankhu1.vn
CVRx reports patient life transformation with Barostim - Traders Union
$CVRX stock is down 14% today. Here's what we see in our data. - Quiver Quantitative
Wolf Popper LLP Announces Investigation on Behalf of CVRx, Inc. Investors - GlobeNewswire
CVRx expects 11-18% revenue growth in 2026 following CPT code transition - Investing.com Nigeria
Chart Watch: Will CVRX stock deliver long term returnsJuly 2025 Selloffs & Risk Adjusted Buy and Sell Alerts - Bộ Nội Vụ
CVRx Establishes At-The-Market Equity Offering Program - The Globe and Mail
CVRx (NASDAQ:CVRX) Stock Price Down 9.9%Here's What Happened - MarketBeat
CVRx (NASDAQ:CVRX) Stock Price Down 9.9% – Here’s What Happened - Defense World
Does CVRx Inc meet Warren Buffetts criteria2025 Breakouts & Breakdowns & High Conviction Buy Zone Picks - baoquankhu1.vn
CVRx reports preliminary 2025 results, issues 2026 guidance - MSN
CVRx Issues 2026 Outlook and Expands Loan Facility - The Globe and Mail
Cvrx reports preliminary fourth quarter and fiscal year 2025 financial results and issues fiscal 2026 guidance - marketscreener.com
Cvrx Incon Jan 9, amends existing loan and security agreement dated Oct 31 2022SEC filing - marketscreener.com
CVRx Signs Loan Agreement Amendment With Innovatus Life Sciences Fund I - TradingView — Track All Markets
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance - GlobeNewswire
Precision Trading with Cvrx Inc. (CVRX) Risk Zones - Stock Traders Daily
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Will CVRx Inc. stock recover faster than marketDip Buying & High Accuracy Investment Signals - ulpravda.ru
Is CVRx Inc. stock a top momentum playEarnings Recap Summary & Weekly High Potential Stock Alerts - ulpravda.ru
Why CVRx Inc. stock is a must watch in 20252025 Dividend Review & Technical Entry and Exit Tips - Улправда
Dividend Watch: Can CVRX stock resist market sell offsQuarterly Profit Review & AI Driven Price Forecasts - Улправда
CVRx: Clinical innovation boosts heart failure care - Traders Union
Aug Spikes: Can CVRX stock beat market expectations this quarterPortfolio Profit Report & Daily Profit Maximizing Tips - moha.gov.vn
CVRx’s Barostim therapy receives Category I CPT codes By Investing.com - Investing.com India
Cvrx announces implementation of new category I CPT codes for Barostim therapy - marketscreener.com
CVRx’s Barostim therapy receives Category I CPT codes - Investing.com
CVRx announces implementation of new category I CPT codes for Barostim therapy - TipRanks
CVRx, Inc. Announces Transition to Category I CPT Codes for Barostim Therapy Effective January 1, 2026 - Quiver Quantitative
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 06 '25 |
Sale |
10.21 |
52,332 |
534,310 |
4,051,098 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 07 '25 |
Sale |
10.00 |
200 |
2,000 |
4,050,898 |
| Nielsen Kirk G. | Director |
May 15 '25 |
Buy |
5.45 |
10,966 |
59,795 |
1,910,134 |
| Nielsen Kirk G. | Director |
May 13 '25 |
Buy |
5.29 |
101,413 |
536,313 |
1,837,968 |
| Nielsen Kirk G. | Director |
May 14 '25 |
Buy |
5.23 |
61,200 |
320,364 |
1,899,168 |
| Nielsen Kirk G. | Director |
May 12 '25 |
Buy |
4.79 |
25,200 |
120,670 |
1,736,555 |
| Jain Mudit K. | Director |
May 12 '25 |
Buy |
4.66 |
1,500 |
6,986 |
4,900 |
2.90%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):